The podocyte: A potential therapeutic target in diabetic nephropathy?

Current Pharmaceutical Design

Volumn 13, Issue 26, 2007, Pages 2713-2720

  Marshall, Sally M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Angiotensin II; Basal cell membrane; Nephrin; p38 MAPK signalling; VEGF receptor 1

Indexed keywords

ACTIN; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIOXIDANT; ATORVASTATIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; NATRIURETIC PEPTIDE TYPE C; NEPHRIN; PENTOXIFYLLINE; PIOGLITAZONE; PROTEIN KINASE C INHIBITOR; REACTIVE OXYGEN METABOLITE; ROBOXYSTAURIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VERY LATE ACTIVATION ANTIGEN 3;

APOPTOSIS; BASEMENT MEMBRANE; CELL DAMAGE; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL SWELLING; CYTOKINE RELEASE; CYTOSKELETON; DIABETIC NEPHROPATHY; DRUG TARGETING; EXPERIMENTAL DIABETES MELLITUS; EXTRACELLULAR MATRIX; GLOMERULUS BASEMENT MEMBRANE; GLYCATION; GLYCEMIC CONTROL; HEMODYNAMIC PARAMETERS; HUMAN; HYPERGLYCEMIA; KIDNEY DYSFUNCTION; MESANGIUM CELL; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETIC NEPHROPATHIES; DRUG DELIVERY SYSTEMS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PODOCYTES;

EID: 34548723974     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781662957     Document Type: Review

References (71)

1. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
2. Sanden S, Elger M, Mundel P, Kritz W. The architecture of podocyte cytoskeleton suggests a role in glomerular filtration haemodynamics. Ann Anat 1995; 177: 44-5.
3. Ruotsalainen V, Patrakka J, Tissari P, Reponen P, Hess M, Kestila M, et al. Role of nephrin in cell junction formation in human nephrogenesis. Am J Pathol 2000; 157: 1905-16.
4. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein-nephrin is mutated in congenital nephritic syndrome. Mol Cell 1998; 1: 575-82.
5. Huber TB, Kottgen M, Schilling B, Walz G, Benzing T. Interaction with podocin facilitates nephrin signalling. J Biol Chem 2001; 276: 41543-6.
6. Huber TB, Hartleben B, Kim J, Schmidts M, Schermer B, Keil A, et al. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signalling. Mol Cell Biol 2003; 23: 4917-28
7. Miner JH. Renal basement membrane components. Kidney Int 1999; 56: 2016-24.
8. Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterisation of podocalyxin, the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 1984; 98: 1591-6.
9. Orlando RA, Takeda T, Zak B, Schmieder S, Benoit VM, McQuistan T, et al. The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 2001; 12: 1589-98.
10. Takeda T, McQuistan T, Orlando RA, Farquhar MG. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 2001; 108: 289-301.
11. Takeda T, Go WY, Orlando RA, Farquhar MG. Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol Biol Cell 2000; 11: 3219-32.
12. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59: 2104-13.
13. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, et al. Viberti GC on behalf of the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes 2002; 51: 3083-9.
14. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fiotetto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-5.
15. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Coplon NS, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 15: 342-8.
16. White KE, Bilous RW. On behalf of the Diabiopsies Study Group. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004; 19: 1437-40
17. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999; 42: 1341-4.
18. Nakamura T, Ushiyama C, Suxuki S, Hara M, Shimada N, Ebihara I, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15: 1379-83.
19. Petermann AT, Pippin J, Krofft R, Blonski M, Griffin S, Durvasula R, et al. Viable podocytes detach in experimental diabetic nephropathy: Potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 2004; 98: 14-23.
20. Regoli M, Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 1997; 40: 15-22
21. Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, Lai YH. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 2000; 67: 2345-53.
22. Aaltonen P, Luimula P, Astrom E, Palmen T, Gronholm T, Palojoki R, et al. Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001; 81: 1185-90.
23. Forbes JM, Bonnet F, Russo LM, Burns WC, Cai Z, Candido R, et al. Modulation of nephrin in the diabetic kidney: Association with systemic hypertension and albuminuria. J Hypertens 2002; 20: 985-92.
24. Kelly DJ, Aaltonen P, Cox AJ, Rumble JR, Langham JR, Panagiotopch Y, et al. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: Differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002; 17: 1327-32.
25. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui IN, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy. Diabetologia 2002; 45: 1572-6.
26. Koop K, Eikmans M, Baelde HJ, Kawachi H, de Heer E, Paul LC, et al. Expresison of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14: 2063-71.
27. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65: 2193-200
28. Ina K, Kitanura H, Nakamura M, Ono J, Takaki P. Loss of sulfated carbohydrate from the glomerular podocyte as a cause of albuminuria in experimental diabetic rats: Ultrastructural histochemical study. J Diabet Complicat 1991; 5: 173-5.
29. Mundel P, Reiser J, Zunuga-Mejia-Borja A, Pavenstadt H, Davidson G, Kritz W, et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-58.
30. Jat PS, Sharp PA. Cell lines established by a temperature-sensitive simian virus 40 large-T-antigen gene are growth restricted at the nonpermissive temperature. Mol Cell Biol 1989; 9: 1672-81.
31. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
32. Kim NH, Rincon-Choles H, Bhandari B, Ghosh Choudhury G, Abboud HE, Gorin Y. Redox dependence of glomerular epithelial cell hypertrophy in response to glucose. Am J Physiol Renal Physiol 2006; 290: F741-51.
33. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of pdoocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-33.
34. Kang SW, Natarajan R, Shahed A, Nast CC, LaPage J, Mundel P, et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003; 14: 3178-87.
35. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and indicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-37.
36. Xu ZG, Yoo TH, Ryu DR, Cheon Park H, Ha SK, Han DS, et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int 2005; 67: 944-52.
37. Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K. p27(Kip1) Knockout mice are protected form diabetic nephropathy: Evidence for p27(Kip1) haplotype insufficiency. Kidney Int 2005; 68: 1583-9.
38. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65: 2193-200
39. Chen S, Lee JS, Iglesias-de la, Cruz MC, Wang A, Izquierdo-Lahuerta, et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: Implications for diabetic nephropathy. Nephrol Dial Transplant 2005; 20: 1320-8.
40. Dessapt C, Hargreaves R, Dei Cas A, Marshall J, Hayward A, Viberti G, et al. Modulation of alpha3-beta1 integrin expression and cell adhesion in glomeurlar podocytes by glucose and mechanical stretch. Diabetic Med 2004; 21(suppl 2): 10-11.
41. Lewko B, Bryl E, Witkowski JM, Latawiec E, Angielski S, Stepinski J. Mechanical stress and glucose concentration modulate glucose transport in cultured rat podocytes. Nephrol Dial Transplant 2005; 20: 306-11
42. Petermann AT, Hiromura K, Bionski M, Pippin J, Monkawa T, Durvasula R, et al. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002; 61: 40-50.
43. Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa T, et al. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 2005; 67: 157-66.
44. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, et al. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62: 901-13.
45. Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3 (IV) collage production by transforming growth factor-beta1 in mouse podocytes. Diabetes 2004; 53: 2939-49.
46. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-34.
47. Schiffer M, Schiffer LE, Gupta A, Shaw AS, Roberts IS, Mundel P, et al. Inhibitory Smads and TGF-beta signalling in glomerular cells. J Am Soc Nephrol 2002; 13: 2657-66.
48. Lewko B, Endlich N, Kriz W, Stepinski J, Endlich K. C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. Kidney Int 2004; 66: 1001-8.
49. Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, et al. Temporal expression profile and distribution pattern indicates a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006; 290: F1344-54.
50. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
51. UK Prospective Diabetes Study. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.
52. Nakamura T, Ushiyama, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50: 1193-6.
53. Cohen MP, Chen S, Ziyadeh FN, Shea E, Hud ES, Lautenslager GT, et al. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria and diabetic nephropathy. Kidney Int 2005; 68: 1554-61.
54. Davila-Esqueda ME, Vertiz-Hernandez AA, Martinez-Moralez F. Comparative analysis of the renoprotective effects of pentoxifylline and Vitamin E on streptozotocin-induced diabetes mellitus. Ren Fail 2005; 27: 115-22.
55. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874-7.
56. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: Potential role of nephrin. J Hypertens 2003; 21: 209-16.
57. Blanco S, Bonet J, Lopez D, Casa I, Romero R. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl. 2005; 93: S10-4.
58. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, et al. Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-30.
59. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, et al. Podocyte foot process broadening in experimental diabetic nephropathy: Amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-82.
60. Gross ML, El-Shakmak A, Szabo A, Koch A, Kuhlmann A, Munter K, et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003; 46: 856-68.
61. Blanco S, Penin R, Casa I, Lopez D, Romero R. Effects of antihypertensive drugs in experimental type 2 diabetes-related nephropathy. Kidney Int Suppl 2002; 82: 27-31.
62. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of roboxystaurin on nephropathy in Type 2. diabetes. Diabetes Care 2005; 28: 2686-90.
63. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831-40.
64. Wang Z, Jiang T, Li J, Proctor G. McManaman JL, Licoa S, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005; 54: 2328-35.
65. Blanco S, Vaquero M, Gomez-Guerrevo C, Lopez D, Egido J. Romero R. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity and mild hypertensión. Am J Hypertens 2005; 18: 557-65.
66. Nakamura T, Kawagoe Y, Ogawa H, Ueda Y, Hara M, Shimada N, et al. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephritic syndrome due to diabetic nephropathy. Am J Kidney Dis 2005; 45: 48-53.
67. Marshall SM. The podocyte: A major player in the development of diabetic nephropathy? Horm Metab Res 2005; 37 (suppl 1): 9-16.
68. Marshall SM. Recent advances in diabetic nephropathy. Clin Med 2004; 4: 277-82.
69. Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005; 11(10): 1291-300.
70. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11(18): 2279-99.
71. Yamagishi S, Matsui T, Nakamura K. Atorvastatin and diabetic vascular complications. Curr Pharm Des 2006; 12(12): 1549-54.